Literature DB >> 18156796

Study of cell-mediated response in mice by HPV16 L1 virus-like particles expressed in Saccharomyces cerevisiae.

Mi-Kyung Woo1, Sook-Jin Hur, Suenie Park, Hong-Jin Kim.   

Abstract

The first vaccine against human papillomaviruses (HPV) formulated with HPV16 L1 virus-like particles (VLPs) produced in yeast was approved by the FDA in June 2006. Nevertheless, there have been few studies of the immunogenicity in mice of VLPs. In this study, we evaluated the cell-mediated immune response to VLPs produced in Saccharomyces cerevisiae. After immunization of mice with HPV16 L1 VLPs, we measured splenocytes proliferation and the levels of IFNgamma, IL2, IL4, and IL5. Splenocytes proliferation was significantly increased and a mixed Th1/Th2 response was indicated. IgG subtype immunoresponses were strongly induced and IgG1 titers were higher than those of IgG2a.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18156796

Source DB:  PubMed          Journal:  J Microbiol Biotechnol        ISSN: 1017-7825            Impact factor:   2.351


  3 in total

1.  The production and immunogenicity of human papillomavirus type 58 virus-like particles produced in Saccharomyces cerevisiae.

Authors:  Hye-Lim Kwag; Hyoung Jin Kim; Don Yong Chang; Hong-Jin Kim
Journal:  J Microbiol       Date:  2012-11-04       Impact factor: 3.422

2.  Preclinical study of safety and immunogenicity of combined rubella and human papillomavirus vaccines: Towards enhancing vaccination uptake rates in developing countries.

Authors:  Asmaa Gohar; Nourtan F Abdeltawab; Nahla Shehata; Magdy A Amin
Journal:  Papillomavirus Res       Date:  2019-06-08

3.  The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles.

Authors:  Hyoung Jin Kim; Su Jeung Lim; Hye-Lim Kwag; Hong-Jin Kim
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.